Allergy Immunotherapies Market Size 2024-2028

The global allergy immunotherapies market size is estimated to grow by USD 1.19 billion, at a CAGR of 9.62% between 2023 and 2028. Market forecasting also includes an in-depth analysis of drivers, trends, and challenges. Our market growth and forecasting report examines historical data from 2018-2022, besides analyzing the current market scenario.

The market is experiencing significant growth due to the efficacy and safety of these treatments, alongside a high prevalence of allergies. Pharmaceutical and biotechnology companies are increasingly focusing on research to develop immunotherapies for various allergies, leading to a notable trend of product approvals in the last five years. These approvals have resulted in the introduction of effective therapies with fewer side effects, improving patient adherence. However, despite recent advancements, there remains a substantial unmet need in the market due to the limited number of approved therapies compared to the prevalence of allergies. To address this gap, companies are conducting extensive research and development, resulting in a robust pipeline of treatments for unaddressed indications. For instance, ALK recently announced positive results from a Phase 3 trial of its sublingual allergy immunotherapy tablet for tree-pollen-induced allergic rhinoconjunctivitis, with plans for market launch. This strong pipeline is anticipated to drive market growth in the forecast period.

What will be the size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Product, Type, and Geography Analysis

The market encompasses Subcutaneous Immunotherapy (SCIT) and Sublingual Immunotherapy (SLIT), which are essential treatments for allergy illnesses in healthcare professionals' arsenals. SCIT, also known as allergy shots, utilizes biologics to stimulate the immune system against allergens. SLIT, represented by medications like Alustal from Stallergenes Greer and Palforzia from Aimmune Therapeutics, involves placing tablets under the tongue for absorption.

Product Analysis

The market share growth by the SCIT segment will be significant during the forecast period. Subcutaneous immunotherapy (SCIT), also known as allergy shots, is the most used type of immunotherapy for the treatment of various allergies. In SCIT, the patients receive small doses of allergen subcutaneously in the arm. Patients receive SCIT for long durations to increase their immunity. SCITs have proven to be highly efficient for the treatment of various respiratory allergies, including allergic rhinitis (hay fever) and asthma.

Get a glance at the market contribution of various segments Download PDF Sample

The SCIT segment was valued at USD 975.60 million in 2018. Despite being highly effective for the treatment of rhinitis and conjunctivitis, the market has witnessed an increasing preference for other treatment options, such as SLIT, resulting in the erosion of market share for the SCIT segment. Also, the recent clinical trial failures of prominent late-stage pipeline molecules, namely immunotherapies from Circassia, are expected to hamper the growth prospects of this segment. In addition, the recent advances in various SLITs are also expected to hamper the market growth of the segment during the forecast period.

Type Analysis

The allergic rhinitis?segment will account for the largest share of this segment.?The market is fueled by the increasing prevalence of allergic rhinitis, a risk factor for various diseases like nasal polyps and sinusitis. Despite rising allergies worldwide, particularly in low- and middle-income countries due to healthcare infrastructure limitations, the market is poised for growth. New therapies for allergy rhinitis, like those being developed by Glenmark Pharmaceuticals, contribute to this momentum. However, the COVID-19 pandemic disrupted the market in 2020-2021 due to lockdowns reducing allergic rhinitis incidence. As vaccination drives lift restrictions, demand for allergy rhinitis drugs is expected to rebound, driving growth in the market.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

Europe is estimated to contribute 51% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. They have witnessed notable demand in Europe, particularly in the context of allergic rhinitis and skin allergies. Food allergies represent a substantial portion of illnesses, with an estimated 2%-37% of Europe's population reporting such sensitivities. Approximately 20% of this population experiences frequent food allergies. Prevalence rates for food allergies are notably high in certain European cities, including Zurich, Madrid, Lodz, Utrecht, Reykjavik, and Athens. Macroeconomic factors, such as pollution and eating habits, contribute to the rising incidence of allergy illnesses.

For instance, alcohol consumption and air pollution have been linked to an increased risk of developing atopic dermatitis. The healthcare system in Europe plays a crucial role in addressing allergy-related health concerns, with medicines like oral immunotherapy and subcutaneous immunotherapy (SCIT), and sublingual immunotherapy (SLIT) being employed to manage allergic conditions. They are essential for managing various allergy-related conditions, including food allergies, atopic dermatitis, and allergic rhinitis. Pollen and respiratory system issues are also common triggers for allergic reactions. As the European population continues to grapple with these health concerns, the demand for effective allergy immunotherapies is expected to persist.

Buy the Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

• Aimmune Therapeutics Inc. - The company offers allergy immunotherapies indicated for the emergency treatment of allergic reactions to stinging and biting insects, allergen immunotherapy, foods, drugs, diagnostic testing substances, and other allergens. 

Adamis Pharmaceuticals Corp., Aimmune Therapeutics Inc., ALK Abello AS, ALLERGOPHARMA GmbH and Co. KG, Allergy Therapeutics PLC , Biomay AG, DBV Technologies SA, Desentum Oy, HAL Allergy BV, Immunomic Therapeutics Inc., Jubilant Pharmova Ltd., LETI Pharma SLU, LOFARMA Spa, Merck KGaA, Novartis AG, Optum Inc., SHIONOGI Co. Ltd., Stallergenes Greer Ltd., Torii Pharmaceutical Co. Ltd., and Viatris Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

In the market, the prevalence of allergies, including cancer and respiratory system-related allergies such as asthma, is a significant concern in emerging economies. Biotechnology and immunology advancements have led to personalized medicine approaches, enabling more effective allergy treatments. Allergic reactions to pollen, air pollution, and other environmental factors continue to challenge the healthcare system, necessitating the development and availability of innovative medicines. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Market Drivers

Increasing prevalence of allergies is the key factor driving the market. Allergy immunotherapies represent a significant growth area within the healthcare industry, particularly for companies specializing in Allergy Immunotherapy. With the prevalence of allergies estimated to impact over 500 million people worldwide, the demand for effective treatment options is increasing. Further, gene therapies are also being explored as potential solutions for allergies, particularly those related to cancer and severe allergic reactions.

Further, physicians and healthcare systems are working together to implement precision medicine approaches, which take into account individual patient characteristics and genetic factors to optimize treatment plans. In summary, the market is poised for growth due to the increasing prevalence of allergies and the development of innovative treatment options. Companies specializing are at the forefront of this trend, leveraging biotechnology, immunology, and personalized medicine to create effective solutions for managing allergic reactions.

Significant Market Trends

Technological advances in allergy diagnostics is the primary trend shaping the market. Allergy immunotherapy companies are at the forefront of addressing the challenges posed by the unclear pathogenesis and prognosis of various indications. Healthcare professionals are in constant pursuit of effective diagnostic methods to accurately identify allergies in their early stages. The current diagnostic tools, including blood tests, skin tests, and patch tests, have limitations. Consequently, numerous research initiatives are underway to develop novel therapies for diagnosing allergies. Emerging economies are witnessing a growing prevalence of allergies due to changing lifestyles and environmental factors.

Further, cancer and allergies share some common immune system responses. Biotechnology and immunology are paving the way for the development of innovative immunotherapies. Precision medicine and healthcare systems are collaborating to provide accurate diagnoses and effective treatments for allergic reactions. In conclusion, the market is witnessing significant advancements in the development of novel diagnostic tools and therapies. Companies are focusing on personalized medicine and precision healthcare to cater to the diverse needs of patients. The immune system's role in allergies and cancer is being explored to develop innovative treatments. The future of the market lies in the integration of biotechnology, immunology, and healthcare systems to provide effective and personalized solutions for managing allergies.

Major Market Challenges

Unknown pathogenesis is the major challenge that affects market growth. Allergy immunotherapies represent a significant market with Allergy Immunotherapy Companies striving to address the challenge of the unclear pathogenesis of various allergies. This ambiguity often leads to misdiagnosis by healthcare professionals, resulting in ineffective treatments and adverse events. Consequently, patients may be deterred from pursuing treatment, negatively impacting drug adoption rates and market expansion. Despite recent approvals of effective SLITs from Stallergenes Greer and ALK Abello AS, featuring products like Alustal and Aimmune Therapeutics' AR101, the risk of side effects persists due to the complex molecular mechanisms underlying allergies. Allergens such as food, grass pollen, dust, and rhinitis or asthma triggers like conjunctivitis can elicit allergic reactions in susceptible individuals.

Additionally, biotechnology and immunology advancements offer potential solutions through personalized medicine and precision medicine approaches, including SCIT and SLIT, as well as gene therapies and oral allergy immunotherapy in the form of tablets. The prevalence of allergies, particularly cancer-associated allergies, necessitates continued research and innovation in the field. Biomarkers and diagnostic tools are crucial in identifying the root causes of allergies, enabling more accurate diagnoses and effective treatments. Merck KGaA (Allergopharma), Hollister Allergy, and Leti Pharma are among the key players contributing to the development of allergy immunotherapies. The immunology community and healthcare systems collaborate to improve patient care and outcomes, ultimately benefiting the market.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecast report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market research report provides comprehensive data (region wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.

• Product Outlook
  • SCIT
  • SLIT

• Type Outlook
  • Allergic Rhinitis
  • Asthma
  • Food Allergy
  • Others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Argentina
    • Australia
    • Brazil

Market Analyst Overview:

Allergy immunotherapies refer to treatments that help the body build a tolerance to allergens, reducing the severity and frequency of allergic reactions. Allergy immunotherapies come in various forms, including sublingual tablets and drops, and subcutaneous injections. The market is significant, driven by the increasing prevalence of allergies worldwide. Allergen sources include pollen, dust mites, animal dander, and foods. The market for these therapies is expanding due to the growing awareness of allergies and the availability of new and effective treatments. Companies are investing in research and development to create more convenient and effective.

Further, the use of advanced technologies, such as biotechnology and nanotechnology, is also contributing to the growth of the market. The market offers a long-term solution for managing allergies, making them a valuable treatment option for patients. Additionally, Allergy immunotherapies like SCIT (Subcutaneous Immunotherapy) and SLIT (Sublingual Immunotherapy) are gaining prominence in Allergy, Asthma & Immunology Research. As highlighted in Current Allergy and Asthma Reports, these therapies offer effective solutions such as allergy shots to alleviate symptoms. With a focus on treating underlying causes, they provide relief for individuals suffering from allergy and asthma. This market expansion reflects growing awareness and investment in advanced treatment options.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size of the size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across Europe, North America, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch